ArticleCancer research2013
Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Clinical and Genomic Characterization of Interval Colorectal Cancer in 3 Prospective Cohorts.Gastroenterology · 2022Pooled it
- Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.Gastroenterology · 2015Trial
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Journal of the National Cancer Institute · 2013Trial
- Impact of acetic acid chromoendoscopy on detection of serrated lesions in the proximal colon compared with white-light endoscopy.Endoscopy international open · 2026Article
- Crosstalk between non-coding RNAs and programmed cell death in colorectal cancer: implications for targeted therapy.Epigenetics & chromatin · 2025Review
- Histologic Reappraisal and Evaluation of MLH1 Protein Expression in Sessile Serrated Lesions of the Proximal Colon.Gastroenterology research and practice · 2025Article
- Colorectal cancer: local results and significance in Hungary.Journal of gastrointestinal oncology · 2024Article
- Molecular Features of the Serrated Pathway to Colorectal Cancer: Current Knowledge and Future Directions.Gut and liver · 2021Review
- Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.JNCI cancer spectrum · 2020Article
- Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia.Cancer causes & control : CCC · 2020Article
- Significance of gene mutations in the Wnt signaling pathway in traditional serrated adenomas of the colon and rectum.PloS one · 2020Article
- DNA methylation instability by BRAF-mediated TET silencing and lifestyle-exposure divides colon cancer pathways.Clinical epigenetics · 2019Article
- Molecular Biomarkers of Sessile Serrated Adenoma/Polyps.Clinical and translational gastroenterology · 2019Article
- The association between colorectal sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia.Cancer causes & control : CCC · 2019Article
- DNA methylation changes that precede onset of dysplasia in advanced sessile serrated adenomas.Clinical epigenetics · 2019Article
- Lifestyle Factors, Colorectal Tumor Methylation, and Survival Among African Americans and European Americans.Scientific reports · 2018Article
- Article
- BRAF inhibitor treatment of melanoma causing colonic polyps: An alternative hypothesis.World journal of gastroenterology · 2017Article
- Molecular genetic changes in benign colorectal tumors synchronous with microsatellite unstable carcinomas do not support a field defect.International journal of molecular epidemiology and genetics · 2017Article
- Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine.Epidemiology (Cambridge, Mass.) · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
A subset of aggressive colorectal cancers exhibit BRAF mutation, MLH1 methylation, and a CpG island methylator phenotype (CIMP), but precursors are poorly established. In this study, we determined the status of these markers in colorectal polyps and evaluated associated risk factors. The study included 771 polyp cases and 1,027 controls who were ages 24 to 80 years, part of a group health program, received a colonoscopy from 1998 to 2007, and completed a structured questionnaire assessing risk factors. Following standard pathology review, polyps were assayed for BRAF mutation (V600E) and tested for MLH1 and CIMP methylation, the latter including the genes, CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1. Polytomous logistic regression was used to estimate ORs and 95% confidence intervals for the association between molecularly defined subsets of polyps and potential risk factors. There were 580 conventional adenomas and 419 serrated lesions successfully assayed. For adenomas, the prevalence of each marker was ≤1%. In contrast, 55% of serrated lesions harbored mutant BRAF, 26% were CIMP-high, and 5% had methylated MLH1. In these lesions, the highest prevalence of markers was in sessile-serrated polyps (SSP) of ≥10 mm that were in the right-side/cecal regions of the colon. Risk factors for CIMP-high-serrated lesions included Caucasian race, current smoking status, and a history of polyps, whereas for serrated lesions with mutant BRAF, the significant risk factors were male sex, current smoking status, obesity, and a history of polyps. Our results suggest that SSPs and other large, right-sided serrated lesions have a unique molecular profile that is similar to CIMP-high, BRAF-mutated colorectal cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.